Gilead Sciences Quarterly Balance Sheet
NASDAQ: GILDHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Gilead Sciences financial position
As of Jun 30, 2026, Gilead Sciences reported total assets of $49.36 billion, down 11.4% from a year earlier against total liabilities of $37.62 billion. Shareholders' equity stood at $11.83 billion, or 24.0% of assets. The company held $3.18 billion in cash and equivalents against $26.25 billion of debt, a net debt position of $23.07 billion.
The current ratio (current assets divided by current liabilities) was 1.27, meaning short-term assets cover obligations due within a year. Debt-to-equity was 2.22.
Summary generated from market data by MetaCap's automated system. Methodology
Gilead Sciences balance sheet (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 3.18B | 7.63B | 7.56B | 7.33B | 5.14B | 7.93B | 9.99B | 5.04B | 2.77B | 4.72B | 6.08B | 5.71B |
| Short-Term Investments | 0 | 15.00M | 68.00M | 19.00M | 69.00M | — | 0 | 0 | 0 | 0 | 1.18B | 1.16B |
| Receivables | 5.05B | 4.74B | 4.91B | 5.09B | 4.78B | 4.39B | 4.42B | 4.59B | 4.66B | 4.67B | 4.66B | 4.79B |
| Inventory | 1.95B | 1.91B | 1.77B | 1.78B | 1.82B | 1.76B | 1.71B | 1.87B | 2.03B | 1.85B | 1.79B | 1.66B |
| Total Current Assets | 13.95B | 18.64B | 18.34B | 17.87B | 14.72B | 16.90B | 19.17B | 14.78B | 12.32B | 14.04B | 16.09B | 15.98B |
| Property, Plant & Equipment | 5.83B | 5.64B | 5.61B | 5.50B | 5.46B | 5.42B | 5.41B | 5.39B | 5.35B | 5.32B | 5.32B | 5.57B |
| Goodwill | 8.31B | 8.31B | 8.31B | 8.31B | 8.31B | 8.31B | 8.31B | 8.31B | 8.31B | 8.31B | 8.31B | 8.31B |
| Intangible Assets | 14.03B | 16.38B | 16.98B | 17.97B | 18.57B | 19.36B | 19.95B | 20.55B | 22.83B | 23.43B | 26.45B | 27.15B |
| Long-Term Investments | 0 | 983.00M | 2.97B | 2.00B | 1.91B | — | 0 | 0 | 0 | 0 | 1.16B | 1.16B |
| Total Assets | 49.36B | 56.28B | 59.02B | 58.53B | 55.72B | 56.43B | 58.99B | 54.52B | 53.58B | 56.29B | 62.13B | 62.37B |
| Accounts Payable | 674.00M | 645.00M | 715.00M | 808.00M | 582.00M | 737.00M | 833.00M | 903.00M | 537.00M | 622.00M | 550.00M | 586.00M |
| Short-Term Debt | 2.41B | 1.31B | 2.81B | 2.81B | 2.81B | 2.81B | 1.81B | 1.81B | 1.81B | 3.67B | 1.80B | 1.79B |
| Total Current Liabilities | 11.02B | 9.48B | 11.81B | 12.30B | 11.19B | 12.34B | 12.00B | 11.72B | 10.78B | 13.02B | 11.28B | 11.95B |
| Long-Term Debt | 23.83B | 20.86B | 22.13B | 22.14B | 22.14B | 22.15B | 24.90B | 21.44B | 21.54B | 21.53B | 23.19B | 23.19B |
| Total Liabilities | 37.62B | 32.85B | 36.41B | 37.08B | 36.13B | 37.36B | 39.75B | 36.13B | 35.38B | 38.84B | 39.38B | 40.13B |
| Shareholders' Equity | 11.83B | 23.52B | 22.70B | 21.54B | 19.67B | 19.16B | 19.33B | 18.48B | 18.28B | 17.54B | 22.83B | 22.31B |
| Retained Earnings | 2.20B | 14.13B | 13.73B | 12.82B | 11.32B | 10.93B | 11.50B | 11.07B | 11.16B | 10.66B | 16.30B | 16.00B |
| Total Debt | 26.25B | 22.17B | 24.94B | 24.94B | 24.95B | 24.95B | 26.71B | 23.25B | 23.35B | 25.19B | 24.99B | 24.98B |
| Net Cash (Debt) | -23.07B | -14.53B | -17.30B | -17.59B | -19.73B | -17.03B | -16.72B | -18.21B | -20.58B | -20.48B | -17.72B | -18.12B |
| Shares Outstanding | 1.24B | 1.24B | 1.24B | 1.24B | 1.24B | 1.25B | 1.25B | 1.25B | 1.25B | 1.25B | 1.25B | 1.25B |
This table shows 12 quarterly periods of Gilead Sciences's balance sheet, from Q2 2026 back to Q3 2023, across 20 line items including cash & equivalents, short-term investments, receivables. Values in USD; B = billions, M = millions. Fiscal periods follow GILD's reporting calendar. What is a balance sheet?